OverviewSuggest Edit

Assertio Therapeutics (formerly Depomed) is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia, and CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults. Besides, the Company provides Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults, and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.

TypePublic
Founded1995
HQNewark, CA, US
Websiteassertiotx.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Dec 2018)116(-31%)
Revenue (FY, 2019)$229.5 M(-26%)
Share Price (Apr 2021)$0.6 (-5%)
Cybersecurity ratingAMore

Key People/Management at Assertio Therapeutics

Dan A. Peisert

Dan A. Peisert

President, Chief Executive Officer & Director
Jack Hoblitzell

Jack Hoblitzell

Senior Vice President, Technical Operations
William T. McKee

William T. McKee

Director
Sarah Longoria

Sarah Longoria

Vice President, Human Resources
Sam Schlessinger

Sam Schlessinger

Vice President, Legal
Paul Schwichtenberg

Paul Schwichtenberg

Senior Vice President, Chief Financial Officer
Show more

Assertio Therapeutics Office Locations

Assertio Therapeutics has offices in Newark and Lake Forest
Newark, CA, US (HQ)
7999 Gateway Blvd STE 300
Lake Forest, IL, US
100 S Saunders Rd Ste 300
Show all (2)

Assertio Therapeutics Financials and Metrics

Assertio Therapeutics Revenue

Embed Graph
View revenue for all periods
Assertio Therapeutics's revenue was reported to be $229.50 m in FY, 2019
USD

Revenue (Q1, 2020)

20.9m

Net income (Q1, 2020)

41.2m

EBIT (Q1, 2020)

(16.6m)

Market capitalization (7-Apr-2021)

98.2m

Closing stock price (7-Apr-2021)

0.6

Cash (31-Mar-2020)

106.0m

EV

(7.5m)
Assertio Therapeutics's current market capitalization is $98.2 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

41.2m27.5m134.2m390.4m342.7m455.9m380.7m311.8m229.5m

Revenue growth, %

191%(12%)33%

Cost of goods sold

5.5m6.0m7.1m15.1m67.9m87.4m72.6m18.5m9.5m

Gross profit

35.6m21.4m127.1m375.2m274.8m368.5m308.1m293.3m220.0m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

70.7m(29.8m)43.3m131.8m(75.7m)(88.7m)(102.5m)36.9m(217.2m)

Depreciation and Amortization

420.0k2.6m6.2m12.0m85.7m109.4m105.5m106.4m104.1m

Inventories

(3.8m)(2.3m)4.3m1.7m9.3m(3.7m)(1.9m)9.0m(316.0k)

Accounts Payable

7.8m5.7m
USDQ2, 2011

Financial Leverage

1.4 x
Show all financial metrics

Assertio Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Assertio Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Assertio Therapeutics Online and Social Media Presence

Embed Graph

Assertio Therapeutics News and Updates

STOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Assertio Therapeutics, Inc. - ASRT

NEW YORK, May 22, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Assertio Therapeutics, Inc. ("Assertio Therapeutics" or the...

Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products

Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million1

Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024

LAKE FOREST, Ill., March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,465,000 in aggregate principal amount of its 2.50% …

Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results

 -- Reports Neurology Franchise Annual Net Sales of $108.1 Million, Exceeding Upper End of Prior Guidance -- -- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million --

Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance

LAKE FOREST, Ill., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced the closing of its previously disclosed agreement (“Agreement”) with Alvogen, a global privately held pharmaceutical company, under which Alvogen will acqu…

Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 Million

LAKE FOREST, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio”) (NASDAQ: ASRT), today announced it has entered into an agreement with Alvogen, a global privately held pharmaceutical company, under which Alvogen will acquire and assume all responsibilities associated w…
Show more

Assertio Therapeutics Blogs

Assertio Therapeutics to Report Third-Quarter 2018 Financial Results After The Close of Markets on Thursday, November 8, 2018

LAKE FOREST, Ill. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release third-quarter 2018 financial results on Thursday, November 8, 2018 , after the close of markets. Following the announcement, the Company will host a conference call

Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Content Import Wed, 08/08/2018 - 22:37 Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) July 6, 2018 at 4:05 PM EDT This release is a backfill from a News Wire …

Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018

Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018 Content Import Wed, 08/08/2018 - 22:37 Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018 July 9, 2018 at 8:31 AM EDT This release is a backf…

Depomed Announces NUCYNTA® Commercialization Agreement with Collegium Pharmaceutical

Depomed Announces NUCYNTA® Commercialization Agreement with Collegium Pharmaceutical Content Import Wed, 08/08/2018 - 22:37 Depomed Announces NUCYNTA® Commercialization Agreement with Collegium Pharmaceutical December 4, 2017 at 4:31 PM EST This release is a b…

Arthur J. Higgins

Arthur J. Higgins deborah.drisco… Thu, 07/26/2018 - 23:10 Arthur J. Higgins

Assertio Therapeutics Frequently Asked Questions

  • When was Assertio Therapeutics founded?

    Assertio Therapeutics was founded in 1995.

  • Who are Assertio Therapeutics key executives?

    Assertio Therapeutics's key executives are Dan A. Peisert, Jack Hoblitzell and William T. McKee.

  • How many employees does Assertio Therapeutics have?

    Assertio Therapeutics has 116 employees.

  • What is Assertio Therapeutics revenue?

    Latest Assertio Therapeutics annual revenue is $229.5 m.

  • What is Assertio Therapeutics revenue per employee?

    Latest Assertio Therapeutics revenue per employee is $2 m.

  • Who are Assertio Therapeutics competitors?

    Competitors of Assertio Therapeutics include Collegium Pharmaceutical, MannKind Corporation and Cisbio.

  • Where is Assertio Therapeutics headquarters?

    Assertio Therapeutics headquarters is located at 7999 Gateway Blvd STE 300, Newark.

  • Where are Assertio Therapeutics offices?

    Assertio Therapeutics has offices in Newark and Lake Forest.

  • How many offices does Assertio Therapeutics have?

    Assertio Therapeutics has 2 offices.